What is the recommended treatment for angioedema and the rationale for each therapy?

Angioedema Treatment and Rationale

For hereditary angioedema (HAE), use C1 inhibitor concentrates, icatibant, or ecallantide for acute attacks—these are the only effective therapies, as epinephrine, antihistamines, and corticosteroids do not work. For histamine-mediated angioedema (with urticaria), use second-generation H1 antihistamines as first-line treatment. 1

Treatment by Angioedema Type

Hereditary Angioedema (HAE) - Acute Attack Management

On-demand therapy is required for ALL patients with HAE, even asymptomatic ones, due to unpredictable attacks and lifelong risk of fatal laryngeal edema. 2

Approved acute treatments (all equally effective when given early): 3, 1

• Plasma-derived C1 inhibitor (pdC1INH): IV administration; replaces deficient C1 inhibitor protein
• Recombinant C1 inhibitor (rhC1INH): IV administration; replacement therapy
• Icatibant: Subcutaneous; blocks bradykinin B2 receptors directly
• Ecallantide: Subcutaneous; inhibits plasma kallikrein (approved age ≥12 years in US)
• Sebetralstat: First oral plasma kallikrein inhibitor (Phase 3 completed) 3

Critical principle: Treat as early as possible in an attack for maximum efficacy. 1

What Does NOT Work for HAE

Epinephrine, corticosteroids, and antihistamines are completely ineffective because HAE is bradykinin-mediated, not histamine-mediated. 1 These standard allergic angioedema treatments do not antagonize bradykinin or stop contact system activation.

Fresh frozen plasma: Controversial—often effective but can paradoxically worsen attacks by providing fresh contact system substrates (prekallikrein, factor XII, high-molecular-weight kininogen) that generate more bradykinin. Use only when specific HAE medications unavailable, with caution. 1

HAE Long-Term Prophylaxis

Indicated when attacks are not controlled with on-demand therapy alone. Consider based on attack frequency, severity, location, access to care, and patient preference. 1

Options (in order of preference based on evidence):

1. Plasma-derived C1INH: 1000 U IV every 3-4 days; most effective, safest option (Grade A evidence) 1
2. Lanadelumab: Anti-kallikrein monoclonal antibody, subcutaneous 4
3. Berotralstat: Oral kallikrein inhibitor 4
4. 17α-alkylated androgens: Effective but significant dose-related side effects; use lowest effective dose (Grade B evidence) 1
5. Antifibrinolytic agents (tranexamic acid/EACA): Least effective prophylactic option (Grade B evidence) 1

Pregnancy consideration: Androgens are contraindicated; use plasma-derived C1INH for prophylaxis. 1

Histamine-Mediated Angioedema (with Urticaria)

Second-generation H1 antihistamines are the cornerstone of therapy. 5, 6

Stepwise approach for chronic spontaneous urticaria with angioedema: 5, 6

1. Standard-dose second-generation H1 antihistamines
2. Up-dose antihistamines (up to 4× standard dose)
3. Add omalizumab, dupilumab, or remibrutinib
4. Consider cyclosporine in refractory cases

For anaphylaxis risk (acute allergic reactions): Add epinephrine and glucocorticoids per guidelines. 5

ACE Inhibitor-Associated Angioedema

Immediately discontinue the ACE inhibitor (or ARB)—this is the definitive treatment. 1 Angioedema can occur within days or after years of therapy.

Acute management:

• Observe in controlled environment for potential intubation
• Antihistamines, corticosteroids, and epinephrine are not effective (bradykinin-mediated mechanism) 1
• Icatibant and fresh frozen plasma show efficacy in open-label reports but lack controlled trial data 1

ARB switching: Modest risk of recurrence exists, but most patients who experienced ACE-I angioedema can safely use ARBs. 1

Acquired C1 Inhibitor Deficiency

Treatment similar to HAE with key differences: 1

• Antifibrinolytic agents MORE effective than in HAE
• C1INH replacement LESS effective (especially with high autoantibody levels)
• Must treat underlying condition (lymphoma, autoimmune disease)
• Consider rituximab for autoantibody-positive cases (sustained remission reported) 1

Critical Airway Management

All oropharyngeal/laryngeal attacks require observation in a facility capable of intubation, regardless of treatment given. 1 Upper airway angioedema is life-threatening and can progress to complete obstruction.

Common Pitfalls to Avoid

1. Do not use antihistamines/steroids/epinephrine for HAE or ACE-I angioedema—wastes time and delays effective treatment
2. Do not perform unnecessary abdominal surgery—HAE abdominal attacks mimic acute abdomen but resolve with appropriate HAE treatment 1
3. Do not use narcotic patches or oxycodone for outpatient HAE pain management—addiction risk is significant 1
4. Do not rely on laboratory parameters to guide prophylaxis dosing—use clinical criteria (attack frequency, severity, quality of life) 1
5. Avoid estrogen-containing contraceptives in HAE patients—dramatically increases attack frequency 1